Logo image of CLSD

CLEARSIDE BIOMEDICAL INC (CLSD) Stock Fundamental Analysis

NASDAQ:CLSD - Nasdaq - US1850631045 - Common Stock - Currency: USD

0.4076  +0.02 (+6.4%)

After market: 0.3901 -0.02 (-4.29%)

Fundamental Rating

2

Overall CLSD gets a fundamental rating of 2 out of 10. We evaluated CLSD against 194 industry peers in the Pharmaceuticals industry. CLSD may be in some trouble as it scores bad on both profitability and health. CLSD is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CLSD had negative earnings in the past year.
In the past year CLSD has reported a negative cash flow from operations.
CLSD had negative earnings in 4 of the past 5 years.
In the past 5 years CLSD always reported negative operating cash flow.
CLSD Yearly Net Income VS EBIT VS OCF VS FCFCLSD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M

1.2 Ratios

With a Return On Assets value of -156.66%, CLSD is not doing good in the industry: 84.46% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -156.66%
ROE N/A
ROIC N/A
ROA(3y)-98.81%
ROA(5y)-77.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CLSD Yearly ROA, ROE, ROICCLSD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 -200 -300

1.3 Margins

CLSD has a better Gross Margin (89.45%) than 92.75% of its industry peers.
The Profit Margin and Operating Margin are not available for CLSD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 89.45%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLSD Yearly Profit, Operating, Gross MarginsCLSD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50K -100K -150K -200K -250K

More info and screens

3

2. Health

2.1 Basic Checks

CLSD does not have a ROIC to compare to the WACC, probably because it is not profitable.
CLSD has more shares outstanding than it did 1 year ago.
CLSD has more shares outstanding than it did 5 years ago.
CLSD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CLSD Yearly Shares OutstandingCLSD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CLSD Yearly Total Debt VS Total AssetsCLSD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

CLSD has an Altman-Z score of -29.08. This is a bad value and indicates that CLSD is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -29.08, CLSD is not doing good in the industry: 83.42% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -29.08
ROIC/WACCN/A
WACC9.76%
CLSD Yearly LT Debt VS Equity VS FCFCLSD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

CLSD has a Current Ratio of 3.19. This indicates that CLSD is financially healthy and has no problem in meeting its short term obligations.
CLSD has a Current ratio (3.19) which is comparable to the rest of the industry.
A Quick Ratio of 3.19 indicates that CLSD has no problem at all paying its short term obligations.
The Quick ratio of CLSD (3.19) is better than 60.10% of its industry peers.
Industry RankSector Rank
Current Ratio 3.19
Quick Ratio 3.19
CLSD Yearly Current Assets VS Current LiabilitesCLSD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

4

3. Growth

3.1 Past

CLSD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.64%, which is quite impressive.
Looking at the last year, CLSD shows a very negative growth in Revenue. The Revenue has decreased by -55.48% in the last year.
CLSD shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -5.17% yearly.
EPS 1Y (TTM)22.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.67%
Revenue 1Y (TTM)-55.48%
Revenue growth 3Y-61.68%
Revenue growth 5Y-5.17%
Sales Q2Q%913.04%

3.2 Future

The Earnings Per Share is expected to grow by 21.27% on average over the next years. This is a very strong growth
CLSD is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 147.00% yearly.
EPS Next Y7.71%
EPS Next 2Y-17.64%
EPS Next 3Y-4.26%
EPS Next 5Y21.27%
Revenue Next Year87.02%
Revenue Next 2Y48.42%
Revenue Next 3Y110.58%
Revenue Next 5Y147%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CLSD Yearly Revenue VS EstimatesCLSD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
CLSD Yearly EPS VS EstimatesCLSD Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CLSD. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLSD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLSD Price Earnings VS Forward Price EarningsCLSD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLSD Per share dataCLSD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

A cheap valuation may be justified as CLSD's earnings are expected to decrease with -4.26% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-17.64%
EPS Next 3Y-4.26%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CLSD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CLEARSIDE BIOMEDICAL INC

NASDAQ:CLSD (8/8/2025, 8:26:25 PM)

After market: 0.3901 -0.02 (-4.29%)

0.4076

+0.02 (+6.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-18 2025-08-18/amc
Inst Owners14.72%
Inst Owner Change3.59%
Ins Owners7.52%
Ins Owner Change0.18%
Market Cap31.67M
Analysts75.38
Price Target4.59 (1026.1%)
Short Float %0.24%
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.13%
Min EPS beat(2)-0.93%
Max EPS beat(2)0.67%
EPS beat(4)3
Avg EPS beat(4)12.06%
Min EPS beat(4)-0.93%
Max EPS beat(4)27.38%
EPS beat(8)5
Avg EPS beat(8)6.63%
EPS beat(12)6
Avg EPS beat(12)-20.66%
EPS beat(16)9
Avg EPS beat(16)-11.73%
Revenue beat(2)2
Avg Revenue beat(2)656.76%
Min Revenue beat(2)69.81%
Max Revenue beat(2)1243.71%
Revenue beat(4)3
Avg Revenue beat(4)502.87%
Min Revenue beat(4)-30.34%
Max Revenue beat(4)1243.71%
Revenue beat(8)6
Avg Revenue beat(8)389.96%
Revenue beat(12)7
Avg Revenue beat(12)263.57%
Revenue beat(16)10
Avg Revenue beat(16)197.85%
PT rev (1m)1.32%
PT rev (3m)-2.94%
EPS NQ rev (1m)2.35%
EPS NQ rev (3m)8.18%
EPS NY rev (1m)2.4%
EPS NY rev (3m)5%
Revenue NQ rev (1m)-65.9%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)11.12%
Revenue NY rev (3m)253.62%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.42
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.41
EYN/A
EPS(NY)-0.62
Fwd EYN/A
FCF(TTM)-0.3
FCFYN/A
OCF(TTM)-0.29
OCFYN/A
SpS0.05
BVpS-0.59
TBVpS-0.59
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -156.66%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 89.45%
FCFM N/A
ROA(3y)-98.81%
ROA(5y)-77.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 328.27%
Cap/Sales 24.68%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.19
Quick Ratio 3.19
Altman-Z -29.08
F-Score2
WACC9.76%
ROIC/WACCN/A
Cap/Depr(3y)1083.74%
Cap/Depr(5y)656.91%
Cap/Sales(3y)33.04%
Cap/Sales(5y)19.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.67%
EPS Next Y7.71%
EPS Next 2Y-17.64%
EPS Next 3Y-4.26%
EPS Next 5Y21.27%
Revenue 1Y (TTM)-55.48%
Revenue growth 3Y-61.68%
Revenue growth 5Y-5.17%
Sales Q2Q%913.04%
Revenue Next Year87.02%
Revenue Next 2Y48.42%
Revenue Next 3Y110.58%
Revenue Next 5Y147%
EBIT growth 1Y-1.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-13.65%
EBIT Next 3Y-31.28%
EBIT Next 5YN/A
FCF growth 1Y4.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y7.29%
OCF growth 3YN/A
OCF growth 5YN/A